Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Acquired by GHP Investment Advisors Inc.

GHP Investment Advisors Inc. increased its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 58.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 50,884 shares of the company’s stock after acquiring an additional 18,819 shares during the quarter. GHP Investment Advisors Inc.’s holdings in Teva Pharmaceutical Industries were worth $782,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Capital Wealth Planning LLC increased its stake in Teva Pharmaceutical Industries by 8.8% in the 4th quarter. Capital Wealth Planning LLC now owns 246,601 shares of the company’s stock valued at $5,435,000 after buying an additional 20,016 shares during the period. Raymond James Financial Inc. acquired a new position in Teva Pharmaceutical Industries in the 4th quarter valued at $38,914,000. Lingotto Investment Management LLP increased its stake in Teva Pharmaceutical Industries by 2.6% in the 4th quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company’s stock valued at $599,320,000 after buying an additional 688,862 shares during the period. LGT Fund Management Co Ltd. acquired a new position in Teva Pharmaceutical Industries in the 4th quarter valued at $3,558,000. Finally, GAMMA Investing LLC increased its stake in Teva Pharmaceutical Industries by 804.7% in the 1st quarter. GAMMA Investing LLC now owns 67,474 shares of the company’s stock valued at $1,037,000 after buying an additional 60,016 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TEVA. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research note on Monday, April 28th. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $21.00 to $23.00 in a research note on Monday, May 12th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Thursday, May 22nd. Truist Financial initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a “buy” rating and a $25.00 price target on the stock. Finally, Bank of America upped their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, May 8th. Nine research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $24.44.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $17.00 on Thursday. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $22.80. The company has a quick ratio of 0.74, a current ratio of 1.03 and a debt-to-equity ratio of 2.59. The firm’s 50-day simple moving average is $16.60 and its 200 day simple moving average is $17.41. The firm has a market capitalization of $19.50 billion, a PE ratio of -14.78, a P/E/G ratio of 0.88 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. The business had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.48 EPS. On average, equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the company’s stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the transaction, the executive vice president now directly owns 9,989 shares in the company, valued at approximately $170,012.78. This represents a 38.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.49% of the stock is owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.